This trial is active, not recruiting.

Condition women with stage i or ii breast cancer undergoing active radiation therapy
Treatment yoga
Sponsor Abramson Cancer Center of the University of Pennsylvania
Start date March 2013
End date July 2015
Trial size 70 participants
Trial identifier NCT01985945, UPCC 08113


The purpose of this study is to examine the use of Eischens yoga for 8 weeks in one cohort of 20 women with stage I and II breast cancer receiving radiation therapy treatment, while a second cohort of the same type of and number of patients who, instead of yoga will receive standard supportive therapy, Questionnaire measuring cancer-related quality of life (FACT-G instrument) and fatigue (Brief Fatique Inventory) will be given to patients at several points.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking open label
Primary purpose supportive care
(No Intervention)

Primary Outcomes

Number of Adverse Events
time frame: One Year

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Stage I and II breast cancer patients undergoing active radiation therapy - Above the age of 18 - Must sign informed consent form - Must speak English - Only women are eligible Exclusion Criteria: - Patients with medical restrictions that may interfere with yoga participation per their physicians' decision - Those who have smoked in the last 6 months because smoking can interfere with the breathing and relaxation techniques of yoga. - Those who have regularly taken yoga in the last 6 months, because they would not come to the intervention with the same baseline as other participants.

Additional Information

Official title A Randomized Study of the Effect of Yoga in Patients With Breast Cancer Receiving Radiation Therapy
Principal investigator Lilie Lin, MD
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Abramson Cancer Center of the University of Pennsylvania.
Location data was received from the National Cancer Institute and was last updated in July 2016.